论文部分内容阅读
目的探索用表面增强拉曼光谱法追踪苯磺酸左旋氨氯地平片的体内消除过程,并对其安全用药提出建议。方法分别采集15例患者的尿液与粪便,通过前处理后与表面信号增强剂等体积混合,以1470±2 cm-l氨氯地平特征峰强度进行检测,计算患者体内消除部分的主药浓度,作出相关分析。结果方法回收率高,RSD在3%以内,尿样中5~100μg·m L-l主药呈良好的线性关系,最低检测限为0.5μg·m L-l;粪样中1~50μg·m L-l主药呈良好的线性关系,最低检测限为1.3μg·m L-l。15例患者中,临床观察到11例患者显效,4例显效不明显。结论所用方法简便迅速,用于二氢吡啶类降压药的体内代谢分析与临床评价尤为适宜。
OBJECTIVE To investigate the in vivo elimination of levamlodipine besylate following surface enhanced Raman spectroscopy and to provide recommendations for its safe use. Methods Urine and excrement were collected from 15 patients. Pre-treatment was followed by equal volume mixing with surface signal enhancer to detect the characteristic peak intensity of amlodipine at 1470 ± 2 cm-1. The concentration of the main drug in the patient’s body was calculated , Make relevant analysis. Results The method showed good recoveries, RSD less than 3% and good linearity of 5-100μg · m Ll in urine samples with the lowest detection limit of 0.5μg · m Ll. The main drug was 1 ~ 50μg · m L Showed a good linear relationship, the minimum detection limit of 1.3μg · m Ll. Among the 15 patients, 11 patients were clinically observed, while 4 patients showed no obvious effect. Conclusion The method is simple and rapid, especially suitable for in vivo metabolism analysis and clinical evaluation of dihydropyridine antihypertensive drugs.